From Bench to Bedside: Targeting Lymphocyte Activation Gene 3 As a Therapeutic Strategy for Autoimmune Diseases

Overview

Journal Inflamm Res

Specialties Allergy & Immunology
Pathology

Date 2023 Jun 14

PMID 37314518

Authors

Xueyin Zhou

Yiming Gu

Huihong Wang

Wei Zhou

Lei Zou

Shuting Li

Chunyan Hua

Sheng Gao

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoints negatively regulate immune response, thereby playing an important role in maintaining immune homeostasis. Substantial studies have confirmed that blockade or deficiency of immune checkpoint pathways contributes to the deterioration of autoimmune diseases. In this context, focusing on immune checkpoints might provide alternative strategies for the treatment of autoimmunity. Lymphocyte activation gene 3 (LAG3), as a member of immune checkpoint, is critical in regulating immune responses as manifested in multiple preclinical studies and clinical trials. Recent success of dual-blockade of LAG3 and programmed death-1 in melanoma also supports the notion that LAG3 is a crucial regulator in immune tolerance.

Methods: We wrote this review article by searching the PubMed, Web of Science and Google Scholar databases.

Conclusion: In this review, we summarize the molecular structure and the action mechanisms of LAG3. Additionally, we highlight its roles in diverse autoimmune diseases and discuss how the manipulation of the LAG3 pathway can serve as a promising therapeutic strategy as well as its specific mechanism with the aim of filling the gaps from bench to bedside.

Citing Articles

Identification of novel autoantibodies in Sjögren's disease.

Engelke F, Budde P, De Vita S, Dorner T, Ernst D, Gras J Front Immunol. 2025; 16:1524940.

PMID: 39963128 PMC: 11830686. DOI: 10.3389/fimmu.2025.1524940.

A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.

Dai T, Sun H, Liban T, Vicente-Suarez I, Zhang B, Song Y Sci Rep. 2024; 14(1):10661.

PMID: 38724599 PMC: 11082181. DOI: 10.1038/s41598-024-61477-6.

References

Cooper G, Stroehla B . The epidemiology of autoimmune diseases. Autoimmun Rev. 2003; 2(3):119-25. DOI: 10.1016/s1568-9972(03)00006-5. View

Chamoto K, Al-Habsi M, Honjo T . Role of PD-1 in Immunity and Diseases. Curr Top Microbiol Immunol. 2017; 410:75-97. DOI: 10.1007/82_2017_67. View

Schnell A, Bod L, Madi A, Kuchroo V . The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Cell Res. 2020; 30(4):285-299. PMC: 7118128. DOI: 10.1038/s41422-020-0277-x. View

Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen A . Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2020; 6(6):865-871. PMC: 7163782. DOI: 10.1001/jamaoncol.2020.0726. View

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

Carney E . Immunology: T-cell exhaustion limits immune reactivity and is associated with good prognosis in autoimmune disease. Nat Rev Nephrol. 2015; 11(9):503. DOI: 10.1038/nrneph.2015.115. View

Joller N, Kuchroo V . Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol. 2017; 410:127-156. PMC: 5902028. DOI: 10.1007/82_2017_62. View

Andrews L, Yano H, Vignali D . Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019; 20(11):1425-1434. DOI: 10.1038/s41590-019-0512-0. View

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S . Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019; 18(1):155. PMC: 6833286. DOI: 10.1186/s12943-019-1091-2. View

10.

Ruffo E, Wu R, Bruno T, Workman C, Vignali D . Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol. 2019; 42:101305. PMC: 6920665. DOI: 10.1016/j.smim.2019.101305. View

11.

Krishnaswamy J, Gowthaman U, Zhang B, Mattsson J, Szeponik L, Liu D . Migratory CD11b conventional dendritic cells induce T follicular helper cell-dependent antibody responses. Sci Immunol. 2017; 2(18). PMC: 7847246. DOI: 10.1126/sciimmunol.aam9169. View

12.

Zhang Q, Vignali D . Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity. 2016; 44(5):1034-51. PMC: 4873959. DOI: 10.1016/j.immuni.2016.04.017. View

13.

Triebel F, JITSUKAWA S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E . LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990; 171(5):1393-405. PMC: 2187904. DOI: 10.1084/jem.171.5.1393. View

14.

Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F . CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995; 25(9):2718-21. DOI: 10.1002/eji.1830250949. View

15.

Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, Maigret B . Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A. 1997; 94(11):5744-9. PMC: 20850. DOI: 10.1073/pnas.94.11.5744. View

16.

Mastrangeli R, Micangeli E, Donini S . Cloning of murine LAG-3 by magnetic bead bound homologous probes and PCR (gene-capture PCR). Anal Biochem. 1996; 241(1):93-102. DOI: 10.1006/abio.1996.0382. View

17.

Li N, Wang Y, Forbes K, Vignali K, Heale B, Saftig P . Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J. 2007; 26(2):494-504. PMC: 1783452. DOI: 10.1038/sj.emboj.7601520. View

18.

Workman C, Vignali D . The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol. 2003; 33(4):970-9. DOI: 10.1002/eji.200323382. View

19.

Hu S, Liu X, Li T, Li Z, Hu F . LAG3 (CD223) and autoimmunity: Emerging evidence. J Autoimmun. 2020; 112:102504. DOI: 10.1016/j.jaut.2020.102504. View

20.

Maeda T, Sugiura D, Okazaki I, Maruhashi T, Okazaki T . Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation. J Biol Chem. 2019; 294(15):6017-6026. PMC: 6463702. DOI: 10.1074/jbc.RA119.007455. View